Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nektar Therapeutics (NKTR), Sarepta Therapeutics (SRPT) and Assertio Therapeutics Inc (ASRT).
Nektar Therapeutics (NKTR)
In a report released today, Difei Yang from Mizuho Securities assigned a Buy rating to Nektar Therapeutics, with a price target of $81. The company’s shares closed yesterday at $32.98, close to its 52-week low of $29.22.
Yang observed:
“We believe these data presentations can be important catalysts for the shares, with potential to continue to show the broad potential of NKTR-214 across many tumor indications.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 11.5% and a 44.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Nektar Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $81.67.
See today’s analyst top recommended stocks >>
Sarepta Therapeutics (SRPT)
Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Sarepta Therapeutics today and set a price target of $231. The company’s shares closed yesterday at $114.50.
Young wrote:
“. We reiterate our Overweight rating and 12-month price target of $231. Sarepta reported an in-line quarter with Exondys sales of $87M, in-line with consensus. For Sarepta, the focus remains on continued pipeline advancement and growing gene therapy manufacturing capabilities. We continue to see many transformative updates for the company over the coming months, including a potential golodirsen approval on 8/19, potential casimersen approval in 1Q2020, and PPMO data around YE19/1Q20. Key trial initiations include commercial microdystrophin by in 2019. We see significant revenue growth ahead with launches and also think the pipeline remains undervalued.”
According to TipRanks.com, Young is a 4-star analyst with an average return of 6.8% and a 45.9% success rate. Young covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Spectrum Pharmaceuticals, and Vertex Pharmaceuticals.
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $207.
Assertio Therapeutics Inc (ASRT)
Mizuho Securities analyst Irina Rivkind Koffler maintained a Hold rating on Assertio Therapeutics Inc today and set a price target of $6. The company’s shares closed yesterday at $4.74.
Rivkind Koffler observed:
“West is the IND holder, and has ongoing dialogue with FDA on the NDA submission, with Assertio acting as an advisor. We hypothesize that the PK issue came up as part of routine information requests during the NDA review process. We believe that there is now a higher risk of a CRL for this product. We expect weakness in the stock, as this is a key pipeline asset, and Assertio’s other meaningful revenue sources decline from 2022- 2025.”
According to TipRanks.com, Koffler is a 3-star analyst with an average return of 1.5% and a 41.2% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Eagle Pharmaceuticals Inc.
Assertio Therapeutics Inc has an analyst consensus of Hold, with a price target consensus of $6.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
